ADARx Pharmaceuticals prices upsized $446.3M IPO at $17 per share
- ADARx Pharmaceuticals priced its upsized IPO at $17.00 per share, raising $446.3 million in gross proceeds.
- AbbVie will invest up to $100.0 million in a concurrent private placement, acquiring approximately 4.9% of outstanding shares.
- Total expected gross proceeds from the IPO and private placement reach $535.2 million before fees.
- Shares are set to begin trading on Nasdaq under the ticker ADRX on September 25, 2026.
*this image is generated using AI for illustrative purposes only.
ADARx Pharmaceuticals, Inc. announced the pricing of its upsized initial public offering of 26,250,000 shares of common stock at $17.00 per share. The offering is expected to generate gross proceeds of approximately $446.3 million for the late-stage biotechnology company.
The shares are scheduled to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol "ADRX". The transaction is expected to close on September 28, 2026, subject to customary closing conditions. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank serve as lead book-running managers, while LifeSci Capital acts as a book-running manager.
Strategic investment from AbbVie
In a concurrent private placement, AbbVie has agreed to purchase shares of ADARx common stock at the same price of $17.00 per share. This purchase will result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares following the closing. The agreement caps AbbVie’s investment at $100.0 million. This private placement is contingent upon the consummation of the initial public offering, though the IPO itself does not depend on the private placement.
Offering details and proceeds
The combined capital raise from the IPO and the private placement is expected to total approximately $535.2 million before deducting underwriting discounts, commissions, and other expenses. Underwriters retain a 30-day option to purchase up to an additional 3,937,500 shares at the public offering price, less discounts and commissions.
| Metric | Value |
|---|---|
| Shares offered | 26,250,000 |
| Price per share | $17.00 |
| Gross IPO proceeds | $446.3 million |
| AbbVie max investment | $100.0 million |
| Total expected proceeds | $535.2 million |
| Over-allotment option | 3,937,500 shares |
What the numbers show
The inclusion of AbbVie as a cornerstone investor provides immediate validation of ADARx’s siRNA therapeutic pipeline. With AbbVie set to hold a 4.9% stake and a prior collaboration license option agreement in place, the company secures both significant capital and strategic alignment with a major pharmaceutical player. The total capital raise of $535.2 million, excluding the over-allotment option, represents a substantial funding event for a pre-commercial biotech firm, covering the gap between clinical development and potential commercialization costs.
How will the specific allocation of the $535.2 million in proceeds impact the timeline for ADARx's lead siRNA candidates entering Phase 3 trials?
What are the potential regulatory or antitrust implications of AbbVie holding a 4.9% stake alongside its existing collaboration license option?
How might the strong institutional demand, evidenced by the upsized offering and anchor investment, influence ADARx's valuation relative to peers in the RNAi space?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
